SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Dermatological map could lead to new treatments
Fri January 22nd - A newly created skin cell map offers a “huge leap” in understanding of disease and could pave the way for potential drug treatments for painful skin diseases, British researchers say. More
Half a million doctors needed for cancer surgery
Fri January 22nd - The world will need half a million more doctors in the next 20 years, just to cope with growing demand for cancer surgery, according to a major new analysis. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 04/08/2020 VICKY P ADAM wrote:
I would like to thank WORLD HERBS CLINIC for reve... on Medieval remedy for bacterial ...
On 29/07/2020 Amdre wrote:
When i read many blogs online about cure to HSV, a... on Medieval remedy for bacterial ...
On 14/07/2020 margret wrote:
I was diagnosed of ALS (amyotrophic lateral sclero... on Heart abnormalities revealed i...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

US vaccine approval draws near

Thursday November 19th 2020

Developers of the first COVID-19 vaccine will be seeking formal approval for use in the USA "within days", it has been announced.

Pfizer released the second tranche of clinical findings from its trial of the mRNA vaccine, claiming 95% efficacy.

It said that efficacy in people over the age of 65 was 94%.

More than 43,000 people have been involved in the randomised trial of the vaccine. Within 28 days of receiving the first dose, 162 cases of infection were detected in those receiving a placebo compared with eight amongst those who were vaccinated.

The company reports that no serious safety concerns have been found. Ten participants developed severe disease – one of them after being vaccinated. The other nine had received the placebo vaccine.

Pfizer said it was ready to deploy 50 million doses of the vaccine this year, using specially designed dry ice packaging to maintain its low temperatures during movement.

It plans to seek approval for emergency use from the US Food and Drug Administration “within days,” stating that the US required safety milestones have been achieved.

Dr Ugur Sahin, founder of BioNTech, the German company that devised the vaccine, said: “These achievements highlight the potential of mRNA as a new drug class. Our objective from the very beginning was to design and develop a vaccine that would generate rapid and potent protection against COVID-19 with a benign tolerability profile across all ages.

“We believe we have achieved this with our vaccine candidate BNT162b2 in all age groups studied so far and look forward to sharing further details with the regulatory authorities.”

* Oxford University researchers have published promising findings from a phase 2 trial of a new Ebola vaccine.

The replication-deficient adenovirus vaccine promotes a strong immune system response after two doses, delivered up to 84 days apart, according to a report in Lancet: Infectious Diseases.

According to the study, high levels of antibodies persist for at least a year after vaccination with the Janssen developed virus.

Researcher Professor Andrew Pollard said: “This is the second Ebola vaccine to be licensed, which means we are now better prepared for future outbreaks of this horrific disease and will be able to pre-emptively vaccinate those who are in the front line.”

Lancet: Infectious Diseases 17 November 2020

[abstract]

Tags: Flu & Viruses | North America | Pharmaceuticals | UK News

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES